Alon_R
$ADMA ASCENIV & SG-001 ✔️
ADMA already traded above $23 last year (before much of the buyback), which is not far from $30 in today's terms.
If we take into account the significant growth of the blockbuster potential ASCENIV franchise, with very strong margins (compared with other options), and SG-001 getting closer, we're talking about triple-digit potential over the next few/several years.
The stock could re-rate significantly higher very quickly as ASCENIV continues delivering strong growth and margins, while constant buybacks provide additional support. ADMA is already a highly profitable biotech, and when SG-001 is ready to go, we're potentially looking at a company with a leadership position in the plasma industry.
12
